The MED board (the “Board”) aims to conform to its statutory responsibilities and industry good practice in relation to corporate governance of MED (“MED” or the “Company”) and its (future) subsidiaries. The Board has adopted the latest version of the QCA Corporate Governance Code (2018) (“QCA Code”) and endeavours to follow its ten principles (“the Principles”) with due regard to the stage of development of the Company. The Company also seeks guidance from its Advisors on recommended best corporate governance practice for LSE companies.

In addition to my role as non – executive chairman of the Board, I am also the chairman of the Company’s Remuneration, Nominations & Governance Committee (the “RNGC”) and as part of the governance remit retain primary responsibility for the design, implementation, articulation, review and updates of the Company’s corporate governance policy. The Governance Committee meets at least once a year and makes recommendations to the Board to ensure the Company’s corporate governance policy remains aligned with the Principles as it grows. 

 Louis Coetzee
(Non-executive Chairman)